

Job Description and Responsibilities

In the context of innovative devices for advanced therapies, the candidate is an enthusiastic sales specialist with previous experience in healthcare-related international business.

The candidate will be responsible for growing the sales of company's proprietary technology in the European market, according to the business plan.

The candidate will identify new key customers, putting into effect sales and business opportunities. He/she will also support the Marketing Manager in building relationships with Early Users and KOLs, as well as create partnerships with clinical and industry stakeholders.

Skills/Attributes

- Relevant experience in sales roles within pharma/life science/medical devices business.
- Technical/scientific degree preferred.
- Ability to identify and prioritize activities according to business opportunities and targets.
- Knowledge of regulatory and clinical guidelines within ATMPs market will be considered a plus.
- Must possess strong communication and listening skills, excellent speaking, reading and writing. Fluency in English is mandatory.

The position requires up to 30% time in travel.

Salary: Based on experience

Location: office-based in Udine.

About VivaBioCell

VivaBioCell is an Italian Company fully owned by the NantWorks Group in Los Angeles.

VivaBioCell mission is to provide smart and cost-effective solutions that allow for the improvement and standardization of advanced therapies manufacturing.

We truly want to inspire the application and diffusion of sustainable advanced therapies, with the long-term vision of bridging regenerative medicine into the mainstream worldwide clinical practice.

Place of employment VivaBioCell S.p.A., Udine	Working Time Full Time	Contract Permanent contract
--	---------------------------	--------------------------------

Write an email to careers@vivabiocell.it attaching your CV to apply to the current job offer.

Visit our website vivabiocell.it to get more information on VivaBioCell and our products.

Udine, 09 January 2020